Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion Pharmaceuticals announced positive Phase 1b/2 results from its ongoing TUPELO trial ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, Recursion announced positive Phase 1b/2 results for REC-4881, which is its ...

Thirty years ago today, Netscape Communications and Sun Microsystems issued a joint press release announcing JavaScript, an object scripting language designed for creating interactive web applications ...

Nov 5 (Reuters) - Apple (AAPL.O), opens new tab plans to use a 1.2 trillion-parameter artificial intelligence model developed by Alphabet's Google (GOOGL.O), opens new tab to help power a revamp of ...

The trend of AI researchers developing new, small open source generative models that outperform far larger, proprietary peers continued this week with yet another staggering advancement. The goal is ...

Google appears to have disabled the &num=100 results parameter, disrupting rank trackers and prompting a rethink of desktop impressions. Many saw desktop impressions drop around Sept. 10. A working ...

One person that helped bring the chill was an analyst cutting his price target. Another two were executives at the biotech selling chunks of stock. 10 stocks we like better than Recursion ...

Hello, and welcome, everybody, to Recursion's Q2 2025 Earnings Call. My name is Chris Gibson, and I'm the Co-Founder and CEO of Recursion. And I'm excited to share with you today some of the latest ...